We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Integrating Multiple Protein Markers Predicts Health Outcomes in Chronic Kidney Disease Patients

By LabMedica International staff writers
Posted on 29 Oct 2024
Print article
Image: Researchers integrated multiple protein markers to predict health outcomes in individuals with chronic kidney disease (Photo courtesy of Adobe Stock)
Image: Researchers integrated multiple protein markers to predict health outcomes in individuals with chronic kidney disease (Photo courtesy of Adobe Stock)

Previous attempts to discover novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have generally focused on evaluating proteins individually, which limits their prognostic capability. Now, a research team has developed and tested new dimensions of kidney health by integrating a combination of 17 urine and plasma biomarkers that have been independently linked to CKD progression.

Investigators at the NIDDK CKD Biomarkers Consortium (Bethesda, MD, USA) evaluated these biomarkers in preserved samples from 1,256 participants across two cohorts: the NIDDK Chronic Renal Insufficiency Cohort (CRIC) and the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. All participants had diabetes and CKD, which was defined as an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m². The researchers identified three health dimensions comprising ten biomarkers: systemic inflammation and filtration (plasma TNFR-1, TNFR-2, suPAR, SDMA), tubular function (urine EGF, ADMA, SDMA), and tubular damage (urine α1m, KIM-1, MCP-1).

Each of these health dimensions was found to be associated with CKD progression or mortality, independent of clinical risk factors and other indicators of kidney function. Notably, higher scores for tubular damage and lower scores for tubular function correlated with an increased risk of CKD progression in one of the studies, while elevated scores for systemic inflammation and kidney filtration were linked to a higher mortality risk in both studies.

“These findings suggest that a multi-biomarker approach could help clarify the wide variation in CKD progression trajectories among persons with diabetes by simultaneously capturing information on glomerular and tubulointerstitial compartments of the kidney,” said corresponding author Vanessa-Giselle Peschard, MD, of UCSF. “Further research will be needed to determine whether these kidney health dimensions could offer prognostic value for individual patients or could be used to monitor the response to medications that impact kidney health.”

Related Links:
CKD Biomarkers Consortium

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.